SANUWAVE Health

SNWV · NASDAQ

$5.27+$0.44 (+9.11%)TodayMarket closed · Oct 20, 5:09 PM ET

Prev close $4.83

SNWV analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 4 analysts

Average $44.37 (+741.9% upside)

Low: $40.40
Now: $5.27
High: $49.35

Upgrades and downgrades

The latest rating actions, newest first

SNWV analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Roth Capital	Mar 30, 2026	Maintains	Buy	$53.00 → $47.00	48%

The case for and against

Updated Jan 19, 2026

Bull case

SANUWAVE Health Inc. demonstrated significant financial growth in the fiscal year 2024, with a notable 60% year-over-year increase in sales, reaching a total of $32.6 million. Additionally, the company achieved an increase in Adjusted EBITDA (AEBITDA) of 28 percentage points, bringing it to 22%, indicating improved operational efficiency and profitability. While operating expenses did rise due to non-cash stock-based compensation and NASDAQ fees, the overall financial trajectory signals a strong position for SANUWAVE in the regenerative medicine market.

Bear case

The financial outlook for SANUWAVE Health appears negative due to a decline in applicator usage during the first quarter, which is typically influenced by seasonal factors such as patients postponing treatments following the reset of annual insurance deductibles. Additionally, the company faces several challenges, including margin compression, competitive pressures, and reduced sales representative productivity, which could hinder future growth. Furthermore, manufacturing setbacks could further impede operational effectiveness and sales performance, creating additional concerns for investors.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.